hypothesis; it is, however, capable of being tested, for if it is true, then among the young Stage C cases histological examination should show a large proportion of highly malignant tumours, whereas, as explained above, among the older Stage C cases there will be some in which invasion has taken place simply because the tumour has been growing for longer, and these may not be particularly malignant.
For Stage A cases metastatic recurrence tends to appear later and to be confined to a single site (usually lungs), and this can also be attributed to differences in malignancy.
The average interval from diagnosis to recurrence is largely independent of age. However, since metastatic growth may have started a considerable time before the diagnosis of the primary, the interval to recurrence may represent a comparatively small proportion of the total period of metastatic growth, particularly for older children. These remarks show that the theoretical model for tumour recurrence put forward by Collins et al. (1956) is irrelevant in the case of a tumour in which 'recurrences' are in fact usually metastatic deposits.
Conclusion
Variations in age and stage at diagnosis of Wilms's tumour are postulated to be due to differences in growth rate and degree of malignancy of the tumour. Variations in tumour size within each age-stage group may be attributed partly to variations in growth rate, partly to fortuitous differences in the presentation of the tumour. Differences in the time of initiation of the tumour doubtless occur, but these may be small.
The results and analyses presented in this paper are intended to provide some insight into factors affecting tumour growth and spread. Also, and of more immediate practical importance, we believe that studies such as this are necessary to provide a basis for planning controlled clinical trials, since only by taking into account the natural history of the disease is it possible to design trials in such a way as to extract the maximum amount of information on the effectiveness of treatment in altering the course of the disease. (I 970) British Medical Journal iv, 195 For some years the Medical Research Council have been organizing extensive co-operative trials of myeloma and leukwemia therapy. These trials involve several centres where patients are allocated at random to particular therapeutic protocols. They are then followed until death. On entry, quite a lot of biochemical and histological information is recorded, and so in principle the trials should show which features are of prognostic importance as well as which therapeutic protocols are best.
With a view to detecting small differences better statistical techniques have been developed in our department. The problem is that when the time comes to analyse a leukxmia trial the data passed on to the statistician are incomplete. For example, he will know the times of death for some patients but for a patient who has been under therapy for, say, two years and who is still alive, the time to death is not known; it is only known to exceed two years. Such incomplete data are almost universal, and only over the past few years have we been able to use them to the full.
The basic approach has been to estimate a death rate for each group: if we arbitrarily define the average death rate for the whole set of patients being studied to be unity, then the average death rates in the various subgroups are called the relative death rates; a subgroup with a relative death rate of less than one has done better than average, whereas a subgroup of patients with a relativedeathrate higher than one has done worse than average: suitable significance tests are available. Table 1 shows the dependence of relative death rate on initial biochemistry in myelomatosis. It was already well known that a high initial blood urea indicated renal failure and therefore carried a poor prognosis, but the dependence of prognosis on albumin was not known. Further investigation showed that the dependence of prognosis on albumin was not attributable to a Section ofEpidemiology & Preventive Medicine 245 common correlation of albumin and prognosis with any of the dozen or so other factors measured, and that after adjustment of prognosis for urea and albumin, none of the other factors then had any further value as predictors of prognosis.
The importance of albumin will, we hope, lead to some completely new discoveries about myelomatosis when we try to find out just why albumin levels matter. They do not seem to be an index of leakage ofalbumin through damaged kidneys since low albumin is not correlated with high urea; the most promising possibility so far suggested is that the more active myelomas actually feed on circulatingalbumin, but further speculation must await the results of radioactive albumin turnover studies.
Summary
We now have statistical techniques that can make use of clinical trial data much more fully than was possible before. As diseases are better understood, so the questions asked by the doctors treating them tend to become more extensive than the straight question of which drug to use; we statisticians are now not only better at detecting the effects of different drugs, we are also for the first time able to deal routinely with this sort of further question. Data from the Oxford Survey of Childhood Cancers have already been used to show that neoplasms which present during childhood are typically embryomas (or growths which originate before the foetus is viable), and that the risk of a diagnostic X-ray causing a cancer is less towards the end of foetal life than at the beginning (Stewart & Kneale 1970a, b) . The purpose of this paper is:
(1) to show that when cancers are initiated shortly before birth they consist mainly of embryomas but also include a small proportion of adult cancers; and (2) to draw attention to certain facts which suggest that rapidly maturing tissues are the first to switch from being the source of em-bryomas to being the source of adult cancers, and that this is why myeloid leukEemia seems to be an exception to the rule that juvenile neoplasms have much shorter latent periods than their adult equivalents.
For this purpose it is necessary to have a representative sample of childhood cancers and to be in a position to classify the cases by cell type and age at the onset of symptoms, and to recognize the onset age distributions of the cases caused by obstetric X-rays (radiogenic cases or third trimester initiations) and the remaining cases (non-radiogenic or idiopathic cases). At present the last requirement can only be met for children who were under 10 years of age when they died, but provided the Oxford Survey continues there is no reason why it should not eventually be met for children who survive until 16 years of age (Kneale 1971) .
The idea that juvenile neoplasms include a high proportion of cases initiated before the foetus is viable is based on the observation that the idiopathic cases in the Oxford Survey were slightly younger than the radiogenic cases (Table 1) . It is also possible to deduce from the onset ages of these cases that the idiopathic cases had more uniform as well as shorter latent periods than the radiogenic ones (see Table 2 ).
When comparing the onset ages of the idiopathic and radiogenic cases it is important to remember that the data describe children who died within ten years of birth, and therefore impose an upper limit of age which could be less than the natural limits for all third trimester initiations, either because embryomas include some slow-growing tumours or because they include adult cancers as well as embryomas. Nevertheless, it would appear that the current follow-up period (0-9 years) has been sufficient for a partial demonstration of the thesis that when cancers are initiated shortly before birth they consist mainly of embryomas but also include a few adult cancers 
